Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9549980 | 0.88 | TPMT (0.46) | PPARATPMTCA12CA1CA2 | |
| SCHEMBL3546860 | 0.81 | TPMT (0.58) | HMGCRPPARAALOX5TPMTPPARG | |
| SCHEMBL8678225 | 0.81 | PPARA (0.51) | HMGCRPTPN1PTPN11PPARATPMT | |
| SCHEMBL9774171 | 0.80 | TPMT (0.55) | PTPN1TPMTCA12CA1CA2 | |
| SCHEMBL5587709 | 0.79 | PTPN1 (0.51) | HMGCRPTPN1PTPN11PPARAALOX5 | |
| SCHEMBL23748617 | 0.79 | PPARA (0.56) | PTPN1PPARAALOX5PPARGPPARD | |
| SCHEMBL10912885 | 0.77 | KDM4E (0.44) | PPARATPMTCA12CA1CA2 | |
| SCHEMBL7095487 | 0.77 | HMGCR (0.49) | HMGCRALOX5 | |
| SCHEMBL8473100 | 0.76 | HMGCR (0.44) | HMGCRPPARAALOX5TPMTPPARG | |
| SCHEMBL9549933 | 0.75 | PTGS2 (0.46) | CA12CA1CA2CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030113275-A1 | Process for the preparation of 1-Propyl-2, 4, 5- trimethoxybenzene from toxic beta-asarone of Acorus calamus or from crude calamus oil containing beta-asarone | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2003-06-19 | — | — | US | disclosed |
| US-6528041-B2 | Organoleptic | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-03-04 | — | — | US | disclosed |
| US-20020035299-A1 | Process for the preparation of 1-Propyl-2, 4, 5-trimethoxybenzene from toxic beta-asarone of acorus calamus or from crude calamus oil containing beta-asarone | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2002-03-21 | — | — | US | disclosed |
| US-5240957-A | Dopaminergic agent | ASTRA LAKEMEDEL AKTEIBOLAG (SE) | 1993-08-31 | — | — | US | disclosed |
| EP-0156776-A1 | Derivatives of N-(2-pyrrolidinylmethyl)-benzamide, process for their preparation, intermediates and a pharmaceutical preparation | Astra Läkemedel Aktiebolag (SE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035299-A1 | Process for the preparation of 1-Propyl-2, 4, 5-trimethoxybenzene from toxic beta-asarone of acorus calamus or from crude calamus oil containing beta-asarone | ADRA2B, CYP1B1, ADRB1 | HMGCR 365/4885PTPN1 3657/4885PTPN11 4519/4885 |
| US-20030113275-A1 | Process for the preparation of 1-Propyl-2, 4, 5- trimethoxybenzene from toxic beta-asarone of Acorus calamus or from crude calamus oil containing beta-asarone | ADRA2B, CYP1B1, ADRB1 | HMGCR 348/4885PTPN1 3686/4885PTPN11 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.